Q&A: Phase 2b trial shows belapectin may be safe for cirrhotic NASH

Galectin Therapeutics has begun a phase 2b/3 clinical trial of belapectin to treat cirrhosis in patients with nonalcoholic steatohepatitis. Healio Gastroenterology spoke with Pol Boudes, MD, chief medical officer of Galectin Therapeutics and Harold Shlevin, PhD, former chief executive officer and a current member of the board of directors, to discuss the design of the trial and their goals for making the drug available to patients with NASH.Healio: Why did you decide to do a trial on belapectin targeting cirrhotic NASH patients?Boudes: Belapectin, a potent galectin-3 inhibitor, is inRead More

Share on facebook
Share on twitter
Share on linkedin